Genomic Valley Bio.
Ticker > Company >

Genomic Valley Bio. share price

Genomic Valley Biotech Ltd.

BSE: 539206 SECTOR: Agriculture  17.57 K   28   2

29.00
-0.88 (-2.95%)
BSE: 03 Jul 4:00 PM

Price Summary

Today's High

₹ 29

Today's Low

₹ 29

52 Week High

₹ 53.49

52 Week Low

₹ 20.1

FinStar is Suspended!

The FinStar rating for this company is currently unavailable due to limited data disclosure. As a micro-cap company, it may carry higher risk and limited transparency. We will update the FinStar rating once more reliable data becomes available.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 8.86 Cr.

Enterprise Value

₹ 8.81 Cr.

No. of Shares

0.31 Cr.

P/E

295.32

P/B

2.25

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  12.86

CASH

₹ 0.05 Cr.

DEBT

₹ 0 Cr.

Promoter Holding

46.06 %

EPS (TTM)

₹  0.1

Sales Growth

411.25%

ROE

9.57 %

ROCE

11.87%

Profit Growth

2245.51 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year411.25%
3 Year128.69%
5 Year-0.06%

Profit Growth

1 Year2245.51%
3 Year242.35%
5 Year4.48%

ROE%

1 Year9.57%
3 Year10.08%
5 Year3.65%

ROCE %

1 Year11.87%
3 Year10.89%
5 Year5.69%

Debt/Equity

0

Price to Cash Flow

329.91

Interest Cover Ratio

2845.3144

CFO/PAT (5 Yr. Avg.)

0

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2026 46.06 0.00
Dec 2025 46.06 0.00
Sep 2025 46.72 0.00
Jun 2025 46.72 0.00
Mar 2025 46.78 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good revenue growth of 128.685747167052% for the Past 3 years.
  • Company is virtually debt free.
  • Company’s PEG ratio is 0.131513775561798.
  • Company has a healthy liquidity position with current ratio of 5.7258.

 Limitations

  • Company has high debtor days of 1026.011.
  • The company has a low EBITDA margin of -101.318341956446% over the past 5 years.
  • The company is trading at a high PE of 295.32.
  • The company is trading at a high EV/EBITDA of 200.7284.

Quarterly Result (All Figures in Cr.)

PARTICULARS Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
Net Sales 0.26 0.09 0.09 0.05 0.04
Total Expenditure 0.26 0.06 0.09 0.04 0.03
Operating Profit 0 0.03 0 0.01 0
Other Income 0 0 0 0 0
Interest 0 0 0 0 0
Depreciation 0 0 0 0 0
Exceptional Items 0 0 0 0 0
Profit Before Tax 0 0.03 0 0.01 0
Tax 0.09 0 0 0 0.01
Profit After Tax -0.08 0.03 0 0.01 -0.01
Adjusted EPS (Rs) -0.27 0.08 0.01 0.04 -0.02

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 0.21 0.07 2.72 0.17 0.84
Total Expenditure 0.34 0.45 1.84 0.15 0.4
Operating Profit -0.14 -0.38 0.88 0.02 0.44
Other Income 0 0.08 0.04 0 0
Interest 0.18 0.04 0 0 0
Depreciation 0.19 0.08 0.01 0 0
Exceptional Items 0 0.42 -0.26 0 0
Profit Before Tax -0.5 0 0.65 0.02 0.44
Tax 0.06 0.01 0 0 0.09
Net Profit -0.56 -0.01 0.65 0.02 0.36
Adjusted EPS (Rs.) -1.83 -0.03 2.12 0.05 1.17

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 3.05 3.05 3.05 3.05 3.05
Total Reserves 1.43 -0.18 0.47 0.49 0.84
Borrowings 1.55 0 0 0 0
Other N/C liabilities 0.7 0.7 0 0 0
Current liabilities 0.87 0.21 0.89 0.79 0.46
Total Liabilities 7.61 3.8 4.42 4.33 4.36
Assets
Net Block 5.86 1.75 0 0 0.01
Capital WIP 0.49 0 0 0 0
Intangible WIP 0 0 0 0 0
Investments 0 0 0 0.02 0
Loans & Advances 1.1 0.91 1.84 1.41 1.73
Other N/C Assets 0 0 0 0 0
Current Assets 0.16 1.14 2.58 2.91 2.62
Total Assets 7.61 3.8 4.42 4.33 4.36
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations -0.5 -0.42 0.91 0.02 0.44
Adjustment 0.19 -0.26 -0.03 0 0
Changes in Assets & Liabilities 1.8 -1.45 -1.66 -0.03 -0.33
Tax Paid 0 0 0 0 -0.09
Operating Cash Flow 1.48 -2.13 -0.78 -0.02 0.03
Investing Cash Flow -1.58 3.67 1.52 -0.02 0.01
Financing Cash Flow 0.07 -1.55 -0.7 0 0
Net Cash Flow -0.03 -0.01 0.04 -0.04 0.04

Corporate Actions

Investors Details

PARTICULARS Mar 2025% Jun 2025% Sep 2025% Dec 2025% Mar 2026%
promoters 46.78 46.72 46.72 46.06 46.06
yogesh agrawal 46.72 46.72 46.72 46.06 46.06
ojaswini avantika 0.07 - - - -
PARTICULARS Mar 2025% Jun 2025% Sep 2025% Dec 2025% Mar 2026%
investors 53.22 53.28 53.28 53.94 53.94
amar aggarwal 9.05 9.05 9.05 9.05 9.05
deepti aggarwal 11.00 11.00 11.00 11.00 11.00
vikram ashokkumar jain 5.50 5.50 5.50 5.50 5.50
wasp tradmart private lim... - - - - 1.25
purushothaman shaji 2.69 3.72 2.64 - -

Annual Reports

Title Link
Title Link
Annual Report 2025
Annual Report 2024
Annual Report 2022
Annual Report 2021
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
 No Credit reports exist for this company.Report us
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Concall related to this company.Report us
TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Presentation related to this company.Report us

Company News

Genomic Valley Biotech informs about newspaper publication 17 Jan, 3:18 PM Genomic Valley - Quaterly Results 16 Jan, 12:00 AM Genomic Valley Biotech informs about updates 1 Jan, 4:21 PM Genomic Valley Biotech informs about AGM 31 Dec, 11:51 AM Genomic Valley Biotech informs about press release 10 Dec, 5:06 PM Genomic Valley - Quaterly Results 16 Oct, 12:00 AM Genomic Valley Biotech submits unaudited standalone financial results 15 Oct, 5:30 PM Genomic Valley - Quaterly Results 7 Aug, 5:18 PM Genomic Valley - Quaterly Results 7 Aug, 5:18 PM Genomic Valley - Quaterly Results 7 Aug, 5:18 PM Genomic Valley - Quaterly Results 14 Feb, 6:10 PM Genomic Valley Biotech informs about disclosure 18 Oct, 12:20 PM Genomic Valley - Quaterly Results 7 Oct, 4:07 PM Genomic Valley - Quaterly Results 7 Oct, 4:07 PM Genomic Valley - Quaterly Results 7 Oct, 4:07 PM Genomic Valley Biotech submits board meeting intimation 3 Oct, 4:38 PM Genomic Valley Biotech informs about disclosure 19 Sep, 11:08 AM Genomic Valley Biotech informs about disclosure 26 Aug, 3:33 PM Genomic Valley Biotech informs about newspaper advertisement 1 Aug, 9:45 AM Genomic Valley - Quaterly Results 29 Jul, 5:55 PM Genomic Valley - Quaterly Results 29 Jul, 5:55 PM Genomic Valley - Quaterly Results 29 Jul, 5:55 PM Genomic Valley - Quaterly Results 9 May, 7:11 PM Genomic Valley - Quaterly Results 9 May, 7:11 PM Genomic Valley Biotech submits compliance certificate 30 Apr, 9:52 AM Genomic Valley - Quaterly Results 14 Feb, 6:48 PM Genomic Valley Biotech informs about certificate 11 Jan, 5:20 PM Genomic Valley - Quaterly Results 10 Feb, 1:58 PM Genomic Valley - Quaterly Results 10 Feb, 1:58 PM Genomic Valley - Quaterly Results 10 Feb, 1:58 PM Genomic Valley Biotech informs about appointment of company secretary 21 Dec, 3:21 PM Genomic Valley Biotech informs about newspaper publication 8 Dec, 2:57 PM Genomic Valley Biotech informs about annual report 7 Dec, 3:55 PM Genomic Valley Biotech informs about disclosure of related party transactions 26 Nov, 3:19 PM Genomic Valley - Quaterly Results 20 Jul, 1:16 PM Genomic Valley - Quaterly Results 20 Jul, 1:16 PM Genomic Valley - Quaterly Results 20 Jul, 1:16 PM Genomic Valley Biotech informs about disclosure 13 May, 4:53 PM Genomic Valley - Quaterly Results 12 Feb, 3:18 PM Genomic Valley Biotech informs about newspaper advertisements 4 Feb, 4:16 PM Genomic Valley Biotech informs about certificate 11 Jan, 2:53 PM Genomic Valley Biotech informs about newspaper advertisements 9 Dec, 4:57 PM Genomic Valley Biotech informs about AGM 8 Dec, 12:37 PM Genomic Valley Biotech informs about book closure 7 Dec, 4:06 PM Genomic Valley Biotech informs about appointment of CS cum CO 6 Dec, 2:02 PM Genomic Valley Biotech informs about outcome of board meeting 25 Nov, 9:49 AM Genomic Valley Biotech informs about trading window closure 1 Nov, 4:27 PM Genomic Valley Biotech informs about board meeting 1 Nov, 4:19 PM Genomic Valley Biotech informs about certificate 14 Oct, 3:47 PM Genomic Valley Biotech informs about board meeting 2 Aug, 3:08 PM

Genomic Valley Bio. Stock Price Analysis and Quick Research Report. Is Genomic Valley Bio. an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Genomic Valley Bio.. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Genomic Valley Bio. has a PE ratio of 295.315682281059 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Genomic Valley Bio. has ROA of 8.1952% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Genomic Valley Bio. has a Current ratio of 5.7258.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Genomic Valley Bio. has a ROE of 9.5721%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Genomic Valley Bio. has a Debt to Equity ratio of 0 which means that the company has low proportion of debt in its capital.

  • Sales growth: Genomic Valley Bio. has reported revenue growth of 411.246% which is fair in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Genomic Valley Bio. for the current financial year is 52.0971292488536%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Genomic Valley Bio. is Rs 0 and the yield is 0%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Genomic Valley Bio. is Rs 0.0982. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Genomic Valley Bio. in Ticker for free. Also, one can get the intrinsic value of Genomic Valley Bio. by using Valuation Calculators, which are available with a Finology ONE subscription. 

Genomic Valley Bio. FAQs

Q1. What is Genomic Valley Bio. share price today?
Ans: The current share price of Genomic Valley Bio. is Rs 29.

Q2. What is the market capitalisation of Genomic Valley Bio.?
Ans: Genomic Valley Bio. has a market capitalisation of Rs 8.85805 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Genomic Valley Bio.?
Ans: The PE ratio of Genomic Valley Bio. is 295.315682281059 and the P/B ratio of Genomic Valley Bio. is 2.25480896325439, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Genomic Valley Bio. share?
Ans: The 52-week high share price of Genomic Valley Bio. is Rs 53.49, and the 52-week low share price of Genomic Valley Bio. is Rs 20.1.

Q5. Does Genomic Valley Bio. pay dividends?
Ans: Currently, Genomic Valley Bio. does not pay dividends. Dividend yield of Genomic Valley Bio. is around 0%.

Q6. What are the face value and book value of Genomic Valley Bio. shares?
Ans: The face value of Genomic Valley Bio. shares is Rs 10, while the book value per share of Genomic Valley Bio. is around Rs 12.8614. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Genomic Valley Bio.?
Ans: Genomic Valley Bio. has a total debt of Rs 0 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Genomic Valley Bio.?
Ans: The ROE of Genomic Valley Bio. is 9.5721% and ROCE of Genomic Valley Bio. is 11.8704%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Genomic Valley Bio. a good buy for the long term?
Ans: The Genomic Valley Bio. long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Genomic Valley Bio. undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Genomic Valley Bio. appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Genomic Valley Bio.’s financials?
Ans: You can review Genomic Valley Bio.’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Genomic Valley Bio.
X